Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1305 of 5804
-
Weekly shot may boost growth in teens with dwarfism
Disease control Recruiting nowThe purpose of this clinical trial is to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of navepegritide 100 μg/kg compared to placebo (inactive drug) in adolescents aged 12 to 18 years with Achondroplasia. What will be measured is Annualized Growth Velocity …
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for muscle stiffness: experimental drug PGN-EDODM1 enters Mid-Stage trial
Disease control Recruiting nowThe purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.
Phase: PHASE2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New mRNA flu vaccine shows promise in early human trial
⭐️ VACCINE ⭐️ CompletedThe goal of this clinical trial is to evaluate the safety and immune responses of three different dose levels a self-amplifying RNA pandemic influenza vaccine (ARCT-2304) in adults. The key objectives of the study are: * To evaluate safety and reactogenicity of different dose le…
Phase: PHASE1 • Sponsor: Arcturus Therapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
-
New hope for Crohn's: experimental drug aims to heal the gut
Disease control Recruiting nowThis is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy o…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug aimed at genetic weakness in blood disorders
Disease control Recruiting nowTo learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Virtual reality could make depression therapy more immersive and effective
Disease control CompletedStudy Overview This study aims to evaluate the effectiveness of a newly developed Virtual Reality (VR) behavioral activation software program for individuals experiencing symptoms of depression. Behavioral activation is a well-established psychological approach that helps individ…
Phase: NA • Sponsor: KTO Karatay University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a Two-Hormone combo beat standard thyroid treatment?
Disease control Recruiting nowHypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied…
Phase: PHASE2, PHASE3 • Sponsor: UConn Health • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New study tests peer support to ease transgender surgery journey
Symptom relief ENROLLING_BY_INVITATIONThe STRIVE study is the first national randomized trial to focus on improving well-being, access to surgical care and other health outcomes for transgender and nonbinary (referred to as trans) people seeking genital gender-affirming surgery (GGAS). Trans people have gender identi…
Phase: NA • Sponsor: Oregon Health and Science University • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New PET scan could predict breast cancer drug success before treatment
Diagnosis Recruiting nowThe objective of the study is to construct a noninvasive approach 68Ga-TTP PET/CT to detect the TROP2 expression of tumor lesions in patients with breast tumors and evaluate the efficacy of ADC drug therapy.
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Precision radiation targets prostate tumors with MRI guidance
Disease control Recruiting nowThe purpose of this study is to assess the impact of this MR-guided radiotherapy on tumor control of the dominant intraprostatic lesion among patients with intermediate risk prostate cancer. This study of Radiotherapy to the Prostate and Dominant Lesion Using Ultra-Hypofractionat…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
One-Dose bone shield for HIV patients? new trial tests zoledronic acid
Prevention Recruiting nowThe goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV. The main questions it aims to answer are: 1. Is bone mass deterioration is…
Phase: PHASE4 • Sponsor: Hadassah Medical Organization • Aim: Prevention
Last updated Jun 26, 2026 17:37 UTC
-
New hope for lung scarring: buloxibutid trial underway
Disease control OngoingThe ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participant…
Phase: PHASE2 • Sponsor: Vicore Pharma AB • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Weekly shot shows promise for shedding pounds in obesity trial
Disease control CompletedThe main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
Phase: PHASE2 • Sponsor: Zealand Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Personalized vaccine + immunotherapy aims to stop bladder cancer return
Disease control Recruiting nowThe original purpose of this study was to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study participants will be enrolled in a safety run-in phase to receive autogene cevum…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for advanced cancers: experimental drug TQB3002 enters human testing
Disease control Recruiting nowThis is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill hopes to stall prostate cancer when other treatments stop working
Disease control Recruiting nowThe purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New MRI could reveal prostate cancer treatment success in weeks
Knowledge-focused Recruiting nowThis study will evaluate the use of hyperpolarized 13C MRI (HP 13C MRI) and the HP-derived 13C pyruvate-to-lactate conversion rate constant (kPL) as an early response biomarker in men with treatment-naïve, high-risk, localized or locally advanced prostate cancer receiving neoadju…
Phase: PHASE2 • Sponsor: Ivan de Kouchkovsky, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Diabetes drug tested as new asthma treatment for overweight patients
Disease control Recruiting nowThis is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New antibody drug shows promise for rare blood cancer
Disease control Recruiting nowThis study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)
Phase: PHASE2 • Sponsor: Gottfried von Keudell, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC